Legal Representation
Attorney
Scott D. Locke
USPTO Deadlines
Next Deadline
1822 days remaining
Section 8 Declaration Due (Principal Register) (Based on registration date 20250204)
Due Date
February 04, 2031
Grace Period Ends
August 04, 2031
Additional deadlines exist. Contact your attorney for complete deadline information.
Application History
16 events| Date | Code | Type | Description | Documents |
|---|---|---|---|---|
| Feb 4, 2025 | NRCC | E | NOTICE OF REGISTRATION CONFIRMATION EMAILED | Loading... |
| Feb 4, 2025 | R.PR | A | REGISTERED-PRINCIPAL REGISTER | Loading... |
| Dec 17, 2024 | NPUB | E | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | Loading... |
| Dec 17, 2024 | PUBO | A | PUBLISHED FOR OPPOSITION | Loading... |
| Dec 11, 2024 | NONP | E | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | Loading... |
| Nov 14, 2024 | ERRR | O | ON HOLD - ELECTRONIC RECORD REVIEW REQUIRED | Loading... |
| Nov 6, 2024 | CNSA | O | APPROVED FOR PUB - PRINCIPAL REGISTER | Loading... |
| Nov 4, 2024 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED | Loading... |
| Nov 4, 2024 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE | Loading... |
| Nov 4, 2024 | TROA | I | TEAS RESPONSE TO OFFICE ACTION RECEIVED | Loading... |
| Sep 26, 2024 | GNRN | O | NOTIFICATION OF NON-FINAL ACTION E-MAILED | Loading... |
| Sep 26, 2024 | GNRT | F | NON-FINAL ACTION E-MAILED | Loading... |
| Sep 26, 2024 | CNRT | R | NON-FINAL ACTION WRITTEN | Loading... |
| Sep 25, 2024 | DOCK | D | ASSIGNED TO EXAMINER | Loading... |
| Aug 8, 2024 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | Loading... |
| Mar 17, 2024 | NWAP | I | NEW APPLICATION ENTERED | Loading... |
Detailed Classifications
Class 005
Therapeutic and prophylactic pharmaceutical products for use in the treatment of cancer, genetic diseases, rare diseases, neurodegenerative diseases and diseases of the immune system; pharmaceutical substances and preparations for use in the treatment of cancer, genetic diseases, rare diseases, neurodegenerative diseases and diseases of the immune system; enzymes and enzyme preparations for medical uses; vectors being gene therapy viral vectors or DNA plasmids for the delivery of genes to cells, all for medical purposes; genetically modified cells for medical use for the treatment of cancer, genetic diseases, rare diseases, neurodegenerative diseases and diseases of the immune system; vectors being gene therapy viral vectors or DNA plasmids for medical use; cell cultures, peptides, proteins, nucleic acids, modified nucleic acids, ribonucleotide protein, mRNA or complexes of these molecules for medical use.
Class 042
Scientific, pharmaceutical and medical research and development in the field of gene modification, gene editing, gene correction, gene repair, gene modulation, cell therapy, cellular modification and gene therapy; genetic engineering services, biotechnology services, advisory services relating to cell therapy and gene therapy products; consultancy and advisory services relating to the aforesaid services.
Classification
International Classes
005
042
Disclaimers
The following terms have been disclaimed and are not claimed as part of the trademark:
Specific Disclaimer
BIOSCIENCES